Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment

Abstract Brain cancers, especially glioblastoma multiforme, are associated with poor prognosis due to the limited efficacy of current therapies. Nanomedicine has emerged as a versatile technology to treat various diseases, including cancers, and has played an indispensable role in combatting the COVID‐19 pandemic as evidenced by the role that lipid nanocarrier‐based vaccines have played. The tunability of nanocarrier physicochemical properties —including size, shape, surface chemistry, and drug release kinetics— has resulted in the development of a wide range of nanocarriers for brain cancer treatment. These nanocarriers can improve the pharmacokinetics of drugs, increase blood‐brain barrier transfer efficiency, and specifically target brain cancer cells. These unique features would potentially allow for more efficient treatment of brain cancer with fewer side effects and better therapeutic outcomes. This review provides an overview of brain cancers, current therapeutic options, and challenges to efficient brain cancer treatment. The latest advances in nanomedicine strategies are investigated with an emphasis on targeted and stimulus‐responsive nanocarriers and their potential for clinical translation.